New Urine Test Shows Promise in Early Autism Detection
A groundbreaking study suggests that a simple urine test could revolutionize the early detection of autism. This development comes as autism affects one in 31 American children, a significant increase from one in 150 in the early 2000s. With such a rise in cases, experts are increasingly focused on identifying potential causes and developing more effective screening tools to detect the condition at an earlier stage.
Currently, doctors rely on questionnaires, observational tests, and cognitive screenings to diagnose autism. However, these methods can be time-consuming, often taking months or even years to reach a conclusion. In contrast, scientists at Arizona State University have developed a urine test that screens for 17 microbial metabolites—molecules produced by microorganisms in the gut.
The results of this test were remarkable. Researchers found that up to nine out of ten children with autism had “extremely high” levels of these metabolites in their urine. This allowed them to distinguish between children with autism and neurotypical children with impressive accuracy. The test was approximately 90% accurate and required only a single sample, significantly reducing the need for extensive screening processes.
Experts believe that these metabolites may act as altered versions of mood-boosting neurotransmitters like serotonin and dopamine. These neurotransmitters play a crucial role in mood, cognition, and memory, which could influence autistic behaviors such as social and speech difficulties. While further research is needed on larger populations, the findings offer hope for earlier diagnosis and improved quality of life for affected children.
Christina Flynn, the first study author and a graduate of Arizona State University, emphasized the potential impact of this discovery. She stated, “What we’ve discovered is that 80 to 90 percent of children with autism have extremely high levels of one or more microbially derived metabolites.” According to Flynn, this test could identify young children at high risk for autism and guide treatment for those already diagnosed, helping them lead better lives.
The study, published in the journal Molecular Psychiatry, involved 52 children with autism and 47 neurotypical children from Arizona, Massachusetts, Tennessee, and Texas. Most participants were from Arizona, and the majority of autistic children were boys. The age range of the participants was from two to 11 years old, with an average age of seven.
Researchers examined 17 metabolites and found six of them to be significantly higher in the autistic group compared to neurotypical children. The average difference ranged from 29 to 228 percent higher. Eight metabolites derived from tryptophan, an amino acid found in proteins like turkey and tuna, were between 38 and 1,882 percent higher in the autistic group.
On average, autistic children had three elevated metabolites, while typically developing children had none. James Adams, the corresponding study author and professor at Arizona State University, explained, “What’s really striking about the bacteria is that they make metabolites that are basically altered versions of serotonin and dopamine.”
These neurotransmitters affect mood, cognition, and memory, potentially explaining many of the symptoms associated with autism, including social communication issues, anxiety, depression, and attention problems. Adams suggested that reducing the levels of these metabolites could help children lead healthier and happier lives, emphasizing the importance of early screening and intervention.
The researchers also highlighted that faster autism diagnosis and earlier interventions have been linked to improved behavior. However, behavioral assessments often involve long wait times. Flynn added, “We hope there is a reduction in stigma and shame associated with the condition.” She noted that diagnostic hesitancy sometimes arises because parents feel judged, but she stressed that autism is a biology-based condition.
The study also points to a possible biological pathway behind autism. The team proposed a new subtype of autism called “ASD associated with microbially-derived metabolites,” or ASD-MDM, which they believe includes 90% of autism cases. Preliminary research suggests that microbiota-based therapies, such as fecal transplants and prebiotics and probiotics, may reduce metabolite levels and improve autistic behaviors. However, the team emphasizes the need for more studies to confirm these findings.
For many families, the waiting period for a diagnosis is one of the biggest challenges. Flynn concluded, “If this test shortens that gap, even by a little, that’s meaningful because earlier intervention can really help.”
